Potentially resectable metastatic colorectal cancer with wild-type KRAS and BRAF: alternating chemotherapy plus cetuximab - A randomised phase II trial - Nordic 8.

Trial Profile

Potentially resectable metastatic colorectal cancer with wild-type KRAS and BRAF: alternating chemotherapy plus cetuximab - A randomised phase II trial - Nordic 8.

Recruiting
Phase of Trial: Phase II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Cetuximab (Primary) ; Fluorouracil; Folinic acid; Irinotecan; Oxaliplatin
  • Indications Colorectal cancer
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms Nordic-8
  • Most Recent Events

    • 20 Jan 2015 Planned End Date changed from 1 Sep 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 20 Jan 2015 Planned primary completion date changed from 1 Sep 2014 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 03 Jun 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01867697).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top